The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The Prognostic Impact of Hypertriglyceridemia and Abdominal Obesity in Acute Myocardial Infarction Patients Underwent Percutaneous Coronary Intervention

관상동맥 중재술을 시행받은 급성심근경색증 환자에서 고중성지방혈증과 복부 비만이 예후에 미치는 영향

  • Oh, Pyung Chun (Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Han, Seung Hwan (Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center)
  • 오병천 (가천대학교 길병원 심장내과) ;
  • 한승환 (가천대학교 길병원 심장내과)
  • Published : 2014.02.01
⟨ Previous Next ⟩

Abstract

Although there are still controversies about whether hypertriglyceridemia is an independent risk factor for coronary artery disease, recent analysis reported hypertriglyceridemia and central obesity are independent risk factors for coronary artery disease. However, the prognostic impact of hypertriglyceridemia and central obesity in acute myocardial infarction (AMI) patients underwent percutaneous coronary intervention (PCI) are still remained unclear. In this issue, Han et al. investigated the prognostic impact of hypertriglyceridemia and/or central obesity on baseline in AMI patients treated with PCI. In this editorial, we have reviewed the role of hypertriglyceridemia and central obesity on the prognosis after PCI in AMI patients. Although hypertriglyceridemia and central obesity on baseline in this study had no role on the prognosis following PCI in AMI patients, to confirm for these results, further studies on this topic will be warranted in the future.

Keywords

References

  1. Gordon T, Kannel WB. Obesity and cardiovascular diseases: the Framingham study. Clin Endocrinol Metab 1976;5:367-375. https://doi.org/10.1016/S0300-595X(76)80026-6
  2. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol 1976;38:46-51. https://doi.org/10.1016/0002-9149(76)90061-8
  3. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130-2139. https://doi.org/10.1016/j.jacc.2006.04.026
  4. Han SG, Jeong MH, Rhee JA, et al. Clinical impact of high triglyceride and central obesity in patients with acute myocardial infarction underwent percutaneous coronary intervention. Korean J Med 2014;86:169-178. https://doi.org/10.3904/kjm.2014.86.2.169
  5. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-949. https://doi.org/10.1016/S0002-9149(00)01127-9
  6. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment. Arch Intern Med 1992;152:28-34. https://doi.org/10.1001/archinte.1992.00400130054004
  7. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888. https://doi.org/10.1001/jama.1996.03540110036029
  8. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(2A):7B-12B. https://doi.org/10.1016/S0002-9149(98)00031-9
  9. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998;19(Suppl A):A2-11.
  10. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-27. https://doi.org/10.1161/01.CIR.102.1.21
  11. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418. https://doi.org/10.1056/NEJM199908053410604
  12. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977. https://doi.org/10.1161/01.CIR.67.5.968
  13. Labounty TM, Gomez MJ, Achenbach S, et al. Body mass index and the prevalence, severity, and risk of coronary artery disease: an international multicentre study of 13,874 patients. Eur Heart J Cardiovasc Imaging 2013;14:456-463. https://doi.org/10.1093/ehjci/jes179
  14. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-1932. https://doi.org/10.1016/j.jacc.2008.12.068
  15. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007;120:863-870. https://doi.org/10.1016/j.amjmed.2007.05.011
  16. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-584. https://doi.org/10.1016/S0735-1097(01)01802-2
  17. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-678. https://doi.org/10.1016/S0140-6736(06)69251-9
  18. Kang WY, Jeong MH, Ahn YK, et al. Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. J Cardiol 2010;55:84-91. https://doi.org/10.1016/j.jjcc.2009.10.004
  19. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005;149:54-60. https://doi.org/10.1016/j.ahj.2004.07.009